Skip to main content

EDITORIAL article

Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1474260
This article is part of the Research Topic RNA Vaccines For Prevalent And Newly Emerging Diseases View all 10 articles

Editorial: RNA Vaccines for Prevalent and Newly Emerging Diseases

Provisionally accepted
Cesar Lopez-Camacho Cesar Lopez-Camacho 1*Mohamad-Gabriel Alameh Mohamad-Gabriel Alameh 2Dan Peer Dan Peer 3Pieter Cullis Pieter Cullis 4
  • 1 University of Oxford, Oxford, United Kingdom
  • 2 University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • 3 Tel Aviv University, Tel Aviv, Tel Aviv, Israel
  • 4 University of British Columbia, Vancouver, British Columbia, Canada

The final, formatted version of the article will be published soon.

    Keywords: Vaccines & Antiviral, RNA, mRNA, mRNA vaccination, emerging pathogens

    Received: 01 Aug 2024; Accepted: 12 Aug 2024.

    Copyright: © 2024 Lopez-Camacho, Alameh, Peer and Cullis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Cesar Lopez-Camacho, University of Oxford, Oxford, United Kingdom

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.